301 related articles for article (PubMed ID: 33376136)
1. Emerging roles of DYRK2 in cancer.
Tandon V; de la Vega L; Banerjee S
J Biol Chem; 2021; 296():100233. PubMed ID: 33376136
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Banerjee S; Wei T; Wang J; Lee JJ; Gutierrez HL; Chapman O; Wiley SE; Mayfield JE; Tandon V; Juarez EF; Chavez L; Liang R; Sah RL; Costello C; Mesirov JP; de la Vega L; Cooper KL; Dixon JE; Xiao J; Lei X
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24881-24891. PubMed ID: 31754034
[TBL] [Abstract][Full Text] [Related]
3. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
[TBL] [Abstract][Full Text] [Related]
4. The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Moreno R; Banerjee S; Jackson AW; Quinn J; Baillie G; Dixon JE; Dinkova-Kostova AT; Edwards J; de la Vega L
Cell Death Differ; 2021 May; 28(5):1563-1578. PubMed ID: 33268814
[TBL] [Abstract][Full Text] [Related]
5. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Taira N; Mimoto R; Kurata M; Yamaguchi T; Kitagawa M; Miki Y; Yoshida K
J Clin Invest; 2012 Mar; 122(3):859-72. PubMed ID: 22307329
[TBL] [Abstract][Full Text] [Related]
6. Stability of the human pregnane X receptor is regulated by E3 ligase UBR5 and serine/threonine kinase DYRK2.
Ong SS; Goktug AN; Elias A; Wu J; Saunders D; Chen T
Biochem J; 2014 Apr; 459(1):193-203. PubMed ID: 24438055
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Morrugares R; Correa-Sáez A; Moreno R; Garrido-Rodríguez M; Muñoz E; de la Vega L; Calzado MA
Cell Mol Life Sci; 2020 Jul; 77(13):2621-2639. PubMed ID: 31605148
[TBL] [Abstract][Full Text] [Related]
8. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Mimoto R; Taira N; Takahashi H; Yamaguchi T; Okabe M; Uchida K; Miki Y; Yoshida K
Cancer Lett; 2013 Oct; 339(2):214-25. PubMed ID: 23791882
[TBL] [Abstract][Full Text] [Related]
9. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
[TBL] [Abstract][Full Text] [Related]
10. Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Correa-Sáez A; Jiménez-Izquierdo R; Garrido-Rodríguez M; Morrugares R; Muñoz E; Calzado MA
Cell Mol Life Sci; 2020 Dec; 77(23):4747-4763. PubMed ID: 32462403
[TBL] [Abstract][Full Text] [Related]
11. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
12. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Park CS; Lewis AH; Chen TJ; Bridges CS; Shen Y; Suppipat K; Puppi M; Tomolonis JA; Pang PD; Mistretta TA; Ma L; Green MR; Rau R; Lacorazza HD
Blood; 2019 Nov; 134(22):1960-1972. PubMed ID: 31515251
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of HSF1 and DYRK2 impedes cancer progression.
Tandon V; Moreno R; Allmeroth K; Quinn J; Wiley SE; Nicely LG; Denzel MS; Edwards J; de la Vega L; Banerjee S
Biosci Rep; 2023 Jan; 43(1):. PubMed ID: 36622366
[TBL] [Abstract][Full Text] [Related]
14. ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.
Taira N; Yamamoto H; Yamaguchi T; Miki Y; Yoshida K
J Biol Chem; 2010 Feb; 285(7):4909-19. PubMed ID: 19965871
[TBL] [Abstract][Full Text] [Related]
15. Engagement of DYRK2 in proper control for cell division.
Nihira NT; Yoshida K
Cell Cycle; 2015; 14(6):802-7. PubMed ID: 25603354
[TBL] [Abstract][Full Text] [Related]
16. Multiple functions of DYRK2 in cancer and tissue development.
Yoshida S; Yoshida K
FEBS Lett; 2019 Nov; 593(21):2953-2965. PubMed ID: 31505048
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase.
Maddika S; Chen J
Nat Cell Biol; 2009 Apr; 11(4):409-19. PubMed ID: 19287380
[TBL] [Abstract][Full Text] [Related]
18. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.
Taira N; Nihira K; Yamaguchi T; Miki Y; Yoshida K
Mol Cell; 2007 Mar; 25(5):725-38. PubMed ID: 17349958
[TBL] [Abstract][Full Text] [Related]
19. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Guo X; Wang X; Wang Z; Banerjee S; Yang J; Huang L; Dixon JE
Nat Cell Biol; 2016 Feb; 18(2):202-12. PubMed ID: 26655835
[TBL] [Abstract][Full Text] [Related]
20. A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation- regulated kinase 2 (DYRK2) in human tumors.
Qiu X; Shen C; Zhao W; Zhang X; Zhao D; Wu X; Yang L
Sci Rep; 2022 Sep; 12(1):15419. PubMed ID: 36104345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
